Holen Sie sich die Stockscreener-App
0.1588
10.33%
-0.0183
Schlusskurs vom Vortag:
$0.1771
Offen:
$0.2106
24-Stunden-Volumen:
162.31M
Relative Volume:
64.86
Marktkapitalisierung:
$6.52M
Einnahmen:
$656.60K
Nettoeinkommen (Verlust:
$-16.79M
KGV:
-0.1478
EPS:
-1.0743
Netto-Cashflow:
$-11.12M
1W Leistung:
-42.75%
1M Leistung:
-57.08%
6M Leistung:
-46.41%
1J Leistung:
-81.67%
1-Tages-Spanne:
$0.1339
$0.214
1-Wochen-Bereich:
$0.1339
$0.276
52-Wochen-Spanne:
$0.1339
$2.60
Scienture Holdings Inc Stock (SCNX) Company Profile
Firmenname
Scienture Holdings Inc
Sektor
Branche
Telefon
(800) 261 0281
Adresse
20 AUSTIN BLVD., COMMACK
Compare SCNX vs HITI, PETS, MEDS, POM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SCNX
Scienture Holdings Inc
|
0.1588 | 11.39M | 656.60K | -16.79M | -11.12M | -1.0743 |
HITI
High Tide Inc
|
2.63 | 248.71M | 486.49M | -33.29M | 10.86M | -0.3627 |
PETS
Petmed Express Inc
|
1.36 | 33.17M | 179.02M | -57.29M | -33.01M | -2.7487 |
MEDS
Trxade Health Inc
|
3.68 | 9.94M | 7.15M | 4.03M | -11.33M | -5.40 |
POM
Pomdoctor Ltd Adr
|
0.86 | 9.64M | 0 | 0 | 0 | 0.00 |
Scienture Holdings Inc Aktie (SCNX) Neueste Nachrichten
Top Premarket Decliners - marketscreener.com
Scienture Holdings (SCNX) Stock Drops 19% After Hours: Here's What Happened - Benzinga
Scienture Holdings Announces Reverse Stock Split - TradingView
These stocks are moving in today's after hours session - ChartMill
Scienture Holdings to implement 1-for-25 reverse stock split - Investing.com
Scienture Holdings, Inc. Announces Reverse Stock Split - The Manila Times
Operating income of Scienture Holdings, Inc. – HAN:4E4 - TradingView
Scienture Holdings, Inc. Statistics – HAN:4E4 - TradingView
Basic earnings per share (basic EPS) of Scienture Holdings, Inc. – HAN:4E4 - TradingView
Scienture Holdings, Inc. (SCNX) Stock Price & News - Syfe
Scienture stock jumps 21% on REZENOPY commercial launch - scanx.trade
SCNX Looks 12.9% Overvalued on GF Value™ - GuruFocus
Premarket Movers: Gainers and Losers for Sept. 22, 2026 - ChartMill
Scienture secures distribution deal for naloxone nasal spray - Investing.com
A nasal spray for opioid overdoses is headed to 2,000 clinics - Stock Titan
Scienture Holdings Inc. (SCNX) Q2 2026 Earnings: EPS Loss Narrower Than Estimated Despite Absence of Reported RevenueDebt Analysis Report - careplusvn.com
SCNX Q2 2026 Earnings: Narrower-Than-Expected Loss Beats Consensus, but Shares SlipEarnings Momentum Score - careplusvn.com
Scienture Holdings (NASDAQ: SCNX) Releases Updated Investor Presentation for Upcoming Analyst Meetings - Kalkine Media
Scienture Holdings Updates Investor Presentation and Guidance - The Globe and Mail
SCNX: Two new therapies launched in 2026 drive revenue growth and pipeline momentum - TradingView
SCNX: Two new therapies launched in 2026 drive revenue growth and pipeline expansion - TradingView
Scienture Holdings at H.C. Wainwright: growth through niche drugs By Investing.com - Investing.com UK
Stay updated with the stocks that are on the move in today's after-hours session. - ChartMill
SCIENTURE to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026 - marketscreener.com
Enterprise value to revenue forward of Scienture Holdings, Inc. – NASDAQ:SCNX - TradingView
Scienture (SCNX) CFO shows no personal stake in company stock - stocktitan.net
Scienture Holdings CFO Eric Sherb files initial beneficial ownership statement - Bitget
SCNX Q2 2026 Earnings: Loss Narrower Than Expected as EPS Beats Estimates by 70.16%ROA Comparison - dars.gov.et
SCNX | Scienture Holdings, Inc. Common FinancialsRevenue Breakdown - Quiver Quantitative
Scienture (SCNX) Levels: Finishes 4.68% Down at $0.45 on the Day; Trading Range: Price Remains Between $0.43 Support and $0.47 Resistance in the Available RecordWyckoff Upthrust - vinanet.vn
Scienture (SCNX) Quarterly Results: Profit Per Share Surpasses Its Benchmark on the Day; Post-Report: Shares Fall 0.49% in the Latest SessionEarnings Growth Forecast - vinanet.vn
Scienture Q2 Revenue Surges 510% Sequentially on Commercial Product Growth - Minichart
Scienture Q2 Revenue Reaches $343,639 as Net Loss Narrows 58% - Quiver Quantitative
Scienture (SCNX) Quarterly Results: Profit Per Share Surpasses Its Benchmark on the Day; Post-Report - dars.gov.et
Scienture (SCNX) Q1 2026 Results: Profit Per Share Clears Its Benchmark in the Latest Session; Closing Reaction: Shares Rise 3.76% in Latest TradingOperating Income Trends - vinanet.vn
$Scienture Holdings (SCNX.US)$ LMAO. They give us a buy rating, but wont let us buy. - Moomoo
SCNX Q1 2026 Earnings: Loss Narrower Than Expected, Shares Rise 2.18%Earnings Analysis - vinanet.vn
SCNX Q1 2026 Earnings: Narrower Loss Beats Estimates, but Shares SlipEarnings Analysis - vinanet.vn
Scienture Holdings 2Q Loss/Shr 7c >SCNX - moomoo.com
Scienture Holdings Reports Q2 2026 Results, Launches REZENOPY™ and Narrows Losses - Quiver Quantitative
SCNX Q2'26 Earnings: EPS estimate is (0.09) USD - TradingView
SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance - The Manila Times
Scienture Holdings: Q2 Earnings Snapshot - marketscreener.com
Scienture Holdings (SCNX) grows ARBLI revenue but remains loss-making in Q2 2026 - Stock Titan
SCIENTURE Launches REZENOPY as Second FDA-Approved Commercial Product - Yahoo Finance
Scienture launches naloxone nasal spray for opioid overdose By Investing.com - Investing.com Nigeria
Scienture launches naloxone nasal spray for opioid overdose - Investing.com
SCIENTURE Announces Commercial Launch and Fulfillment of Initial Purchase Orders of REZENOPY™, the Highest Dose FDA-Approved Naloxone Nasal Spray - marketscreener.com
Scienture Holdings Announces Commercial Launch and Fulfillment of Initial Purchase Orders of Rezenopy Nasal Spray 10 Mg - marketscreener.com
EXCLUSIVE: Scienture Launches Highest-Dose Naloxone Nasal Spray Rezenopy in US - Yahoo Finance
Scienture Holdings Inc expected to post a loss of 23 cents a shareEarnings Preview - TradingView
Finanzdaten der Scienture Holdings Inc-Aktie (SCNX)
Umsatz
Nettogewinn
Free Cashflow
ENV
6.52%
2.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):